Eris to buy Biocon arm’s branded drugs for 1,242 crore – Times of India
[ad_1] NEW DELHI: Biocon is selling branded formulations of its subsidiary Biocon Biologics to Eris Lifesciences for Rs 1,242 crore. The deal will jumpstart Eris’s entry into the over Rs 30,000-crore injectables market in India, and become a leading player in the insulins segment, with acquisition of two major brands – Basalog and Insugen. It…